Meridian Bioscience (VIVO) 10-K 29 Nov 16 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Sep. 30, 2016	Oct. 31, 2016	Mar. 31, 2016
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Trading Symbol	VIVO
Entity Registrant Name	MERIDIAN BIOSCIENCE INC
Entity Central Index Key	794,172
Current Fiscal Year End Date	--09-30
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		42,108,217
Entity Public Float			$ 856,265,348

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Net Revenues	$ 196,082	$ 194,830	$ 188,832
Cost of Sales	68,295	72,948	71,589
Gross Profit	127,787	121,882	117,243
Operating Expenses
Research and development	13,815	12,605	12,552
Selling and marketing	29,871	25,601	24,910
General and administrative	30,565	27,616	27,389
Acquisition-related costs	1,481
Sales and marketing leadership reorganization costs	677
Total operating expenses	76,409	65,822	64,851
Operating Income	51,378	56,060	52,392
Other Income (Expense)
Interest income	67	23	25
Interest expense	(897)
Other, net	96	(1,020)	(309)
Total other income (expense)	(734)	(997)	(284)
Earnings Before Income Taxes	50,644	55,063	52,108
Income Tax Provision	18,415	19,523	17,365
Net Earnings	$ 32,229	$ 35,540	$ 34,743
Earnings Per Share Data
Basic earnings per common share	$ 0.77	$ 0.85	$ 0.84
Diluted earnings per common share	$ 0.76	$ 0.85	$ 0.83
Common shares used for basic earnings per common share	42,010	41,659	41,455
Effect of dilutive stock options and restricted shares and units	383	353	458
Common shares used for diluted earnings per common share	42,393	42,012	41,913
Dividends declared per common share	$ 0.80	$ 0.80	$ 0.79
Anti-dilutive Securities:
Common share options and restricted shares and units	462	551	272

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2014
Statement of Comprehensive Income [Abstract]
Net Earnings	$ 32,229	$ 35,540	$ 34,743
Other comprehensive income (loss):
Foreign currency translation adjustment	(2,732)	(2,639)	(436)
Unrealized loss on cash flow hedge	(729)
Income taxes related to items of other comprehensive income	275
Other comprehensive income (loss), net of tax	(3,186)	(2,639)	(436)
Comprehensive Income	$ 29,043	$ 32,901	$ 34,307

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2016	Sep. 30, 2015
Current Assets
Cash and equivalents	$ 47,226	$ 49,973
Accounts receivable, less allowances of $334 and $248, respectively	27,102	26,254
Inventories	45,057	35,817
Prepaid expenses and other current assets	7,406	7,378
Total current assets	126,791	119,422
Property, Plant and Equipment, at Cost
Land	1,155	1,068
Buildings and improvements	31,487	29,974
Machinery, equipment and furniture	45,085	41,541
Construction in progress	1,947	1,139
Subtotal	79,674	73,722
Less: accumulated depreciation and amortization	49,224	46,230
Net property, plant and equipment	30,450	27,492
Other Assets
Goodwill	61,982	22,349
Other intangible assets, net	29,855	5,931
Restricted cash	1,000	1,000
Deferred instrument costs, net	1,392	1,750
Deferred income taxes		4,954
Other assets	353	384
Total other assets	94,582	36,368
Total assets	251,823	183,282
Current Liabilities
Accounts payable	7,627	6,646
Accrued employee compensation costs	7,106	5,132
Other accrued expenses	2,606	2,587
Current portion of long-term debt	3,750
Income taxes payable	1,482	886
Total current liabilities	22,571	15,251
Non-Current Liabilities
Acquisition consideration	2,383
Non-current compensation liabilities	2,305	2,158
Interest rate swap liability	729
Long-term debt	54,610
Deferred income taxes	2,753
Total non-current liabilities	62,780	2,158
Commitments and Contingencies
Shareholders' Equity
Preferred stock, no par value; 1,000,000 shares authorized; none issued
Common shares, no par value; 71,000,000 shares authorized, 42,106,587 and 41,838,399 issued, respectively	0	0
Additional paid-in capital	122,356	117,151
Retained earnings	49,632	51,052
Accumulated other comprehensive loss	(5,516)	(2,330)
Total shareholders' equity	166,472	165,873
Total liabilities and shareholders' equity	$ 251,823	$ 183,282

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2016	Sep. 30, 2015
Statement of Financial Position [Abstract]
Allowances for accounts receivable	$ 334	$ 248
Preferred stock, par value
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Common stock, par value
Common stock, shares authorized	71,000,000	71,000,000
Common stock, shares issued	42,106,587	41,838,399

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Shares Issued [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accum Other Comp Income (Loss) [Member]
Beginning balance at Sep. 30, 2013	$ 155,045		$ 107,412	$ 46,888	$ 745
Beginning balance, Shares at Sep. 30, 2013		41,518
Cash dividends paid	(32,762)			(32,762)
Exercise of stock options	882		882
Exercise of stock options, Shares		78
Issuance of restricted shares, net of forfeitures		(1)
Conversion of restricted stock units	0	$ 0	0	0	0
Conversion of restricted stock units, Shares		27
Stock compensation expense	3,557		3,557
Net Earnings	34,743			34,743
Foreign currency translation adjustment	(436)				(436)
Ending balance at Sep. 30, 2014	161,029		111,851	48,869	309
Ending balance, Shares at Sep. 30, 2014		41,622
Cash dividends paid	(33,357)			(33,357)
Exercise of stock options	1,976		1,976
Exercise of stock options, Shares		187
Conversion of restricted stock units	0	$ 0	0	0	0
Conversion of restricted stock units, Shares		29
Stock compensation expense	3,324		3,324
Net Earnings	35,540			35,540
Foreign currency translation adjustment	(2,639)				(2,639)
Ending balance at Sep. 30, 2015	165,873		117,151	51,052	(2,330)
Ending balance, Shares at Sep. 30, 2015		41,838
Cash dividends paid	(33,649)			(33,649)
Exercise of stock options	$ 2,294		2,294
Exercise of stock options, Shares	152	152
Conversion of restricted stock units	$ 0	$ 0	0	0	0
Conversion of restricted stock units, Shares		117
Stock compensation expense	2,911		2,911
Net Earnings	32,229			32,229
Foreign currency translation adjustment	(2,732)				(2,732)
Hedging activity, net of tax	(454)				(454)
Ending balance at Sep. 30, 2016	$ 166,472		$ 122,356	$ 49,632	$ (5,516)
Ending balance, Shares at Sep. 30, 2016		42,107

Consolidated Statements of Sha7

Consolidated Statements of Shareholders' Equity (Parenthetical) - $ / shares	3 Months Ended								12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2014
Statement of Stockholders' Equity [Abstract]
Cash dividends per common share	$ 0.20	$ 0.20	$ 0.20	$ 0.20	$ 0.20	$ 0.20	$ 0.20	$ 0.20	$ 0.80	$ 0.80	$ 0.79

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2014
Cash Flows From Operating Activities
Net Earnings	$ 32,229	$ 35,540	$ 34,743
Non-cash items included in net earnings:
Depreciation of property, plant and equipment	3,937	3,470	3,523
Amortization of intangible assets	2,690	1,748	2,039
Amortization of deferred instrument costs	1,091	1,391	1,702
Stock-based compensation	2,911	3,324	3,557
Deferred income taxes	(233)	(122)	(140)
Losses on long-lived assets	659	94	6
Change in current assets, net of acquisition	(8,115)	(6,079)	(1,528)
Change in current liabilities, net of acquisition	2,237	3,238	(5,996)
Other, net	(183)	205	356
Net cash provided by operating activities	37,223	42,809	38,262
Cash Flows From Investing Activities
Purchases of property, plant and equipment	(4,004)	(4,613)	(5,306)
Purchase of equity method investment	(600)
Proceeds from sale of assets		1,138
Purchases of intangibles and other assets		(151)	(1,696)
Acquisition of Magellan, net of cash acquired	(62,091)
Net cash used for investing activities	(66,695)	(3,626)	(7,002)
Cash Flows From Financing Activities
Dividends paid	(33,649)	(33,357)	(32,762)
Proceeds from term loan, net of issuance costs	59,860
Payments on term loan	(1,500)
Proceeds and tax benefits from exercises of stock options	2,494	2,614	1,009
Net cash provided by (used for) financing activities	27,205	(30,743)	(31,753)
Effect of Exchange Rate Changes on Cash and Equivalents	(480)	(1,514)	(742)
Net (Decrease) Increase in Cash and Equivalents	(2,747)	6,926	(1,235)
Cash and Equivalents at Beginning of Period	49,973	43,047	44,282
Cash and Equivalents at End of Period	47,226	49,973	43,047
Supplemental Cash Flow Information
Cash paid for interest	879
Cash paid for income taxes	$ 17,915	$ 20,168	$ 19,952

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	(1) Summary of Significant Accounting Policies (a) Nature of Business - (b) Principles of Consolidation - (c) Use of Estimates - (d) Foreign Currency Translation (e) Cash, Cash Equivalents and Investments - Our investment portfolio includes the following components: September 30, 2016 September 30, 2015 Cash and Other Cash and Other Overnight repurchase agreements $ 9,988 $ — $ 25,436 $ — Institutional money market funds 10,020 — — — Cash on hand – Restricted — 1,000 — 1,000 Unrestricted 27,218 — 24,537 — Total $ 47,226 $ 1,000 $ 49,973 $ 1,000 (f) Inventories illumi gene illumi gene We establish reserves against cost for excess and obsolete materials, finished goods whose shelf life may expire before sale to customers, and other identified exposures. Such reserves were $2,680 and $2,456 at September 30, 2016 and 2015, respectively. We estimate these reserves based on assumptions about future demand and market conditions. If actual demand and market conditions were to be less favorable than such estimates, additional inventory write-downs would be required and recorded in the period known. Such adjustments would negatively affect gross profit margin and overall results of operations. (g) Property, Plant and Equipment Buildings and improvements - 18 to 40 years Machinery, equipment and furniture - 3 to 10 years Computer equipment and software - 3 to 5 years (h) Intangible Assets - During fiscal 2016, the annual impairment review for our Americas Diagnostics reporting unit consisted of a qualitative assessment. A qualitative assessment is first performed to determine whether it was more likely than not that the fair value of the reporting unit is less than its carrying value using qualitative indicators. In the event that the reporting unit does not pass the qualitative assessment, the reporting unit’s carrying value is compared to its fair value, with fair value of the reporting unit estimated using market and discounted cash flow approaches. Our Americas Diagnostics reporting unit satisfied the qualitative assessment for fiscal 2016. For each of our Bioline and Life Science-U.S. reporting units, we performed a quantitative assessment in order to determine if impairment existed. As part of this assessment, fair value, as determined through a valuation performed by a third party, was calculated via both market (comparable company) and income (discounted cash flows) approaches. Based upon these approaches, as well as an average of the two, the fair values of each reporting unit exceeded their carrying values; therefore, both the Bioline and Life Science-U.S. reporting units satisfied the quantitative assessment for fiscal 2016. The goodwill held by our Magellan reporting unit was recorded at estimated fair value as part of the March 24, 2016 acquisition (see Note 2) and no events have occurred since that date that would indicate the existence of an impairment. Goodwill is considered impaired if the carrying value of the reporting unit exceeds its fair value. We have no intangible assets with indefinite lives other than goodwill. There have been no impairments from the analyses performed for fiscal 2016, 2015 or 2014. During fiscal 2016, goodwill increased $39,633, reflecting $41,358 from the acquisition of Magellan (Diagnostics operating segment; see Note 2) and a $1,725 decrease from the currency translation adjustment on the goodwill of the Life Science segment’s Bioline Group. The decrease of $844 in fiscal 2015 solely reflects the effect of the Bioline Group and the currency translation adjustments thereon. A summary of Meridian’s acquired intangible assets subject to amortization, as of September 30, 2016 and 2015 is as follows: 2016 2015 As of September 30, Gross Accum. Gross Accum. Manufacturing technologies, core products and cell lines $ 21,921 $ 11,540 $ 11,582 $ 10,906 Trade names, licenses and patents 9,037 3,947 6,410 3,296 Customer lists, customer relationships and supply agreeements 24,385 10,511 12,105 9,964 Non-compete agreements 680 170 — — $ 56,023 $ 26,168 $ 30,097 $ 24,166 The actual aggregate amortization expense for these intangible assets for fiscal 2016, 2015 and 2014 was $2,690, $1,748 and $2,039, respectively. The estimated aggregate amortization expense for these intangible assets for each of the five succeeding fiscal years is as follows: fiscal 2017 - $3,671, fiscal 2018 - $3,480, fiscal 2019 - $3,269, fiscal 2020 - $3,107 and fiscal 2021 - $2,510. Long-lived assets, excluding goodwill, are reviewed for impairment when events or circumstances indicate that such assets may not be recoverable at their carrying value. Whether an event or circumstance triggers an impairment is determined by comparing an estimate of the asset’s future undiscounted cash flows to its carrying value. If impairment has occurred, it is measured by a fair-value based calculation. Our ability to recover the carrying value of our intangible assets, both identifiable intangibles and goodwill, is dependent upon the future cash flows of the related acquired businesses and assets. We make judgments and assumptions regarding future cash flows, including sales levels, gross profit margins, operating expense levels, working capital levels, and capital expenditures. With respect to identifiable intangibles and fixed assets, we also make judgments and assumptions regarding useful lives. We consider the following factors in evaluating events and circumstances for possible impairment: (i) significant under-performance relative to historical or projected operating results; (ii) negative industry trends; (iii) sales levels of specific groups of products (related to specific identifiable intangibles); (iv) changes in overall business strategies; and (v) other factors. If actual cash flows are less favorable than projections, this could trigger impairment of intangible assets and other long-lived assets. If impairment were to occur, this would negatively affect overall results of operations. No triggering events have been identified by the Company for fiscal 2016, 2015 or 2014. (i) Revenue Recognition and Accounts Receivable Revenue for our Diagnostics segment includes revenue for our illumi gene We evaluate whether each deliverable in the arrangement is a separate unit of accounting. The significant deliverables are an instrument, instrument accessories (e.g., printer) and test kits. An instrument and instrument accessories are delivered to the customer prior to the start of the customer utilization period in order to accommodate customer set-up and installation. There is de minimis illumi gene In markets where the test system is not sold via multiple deliverable arrangements, the cost of the instrument and instrument accessories is charged to cost of sales at the time of shipment and transfer of title to the customer. Revenue for the sales of instruments and instrument accessories and test kits is recognized upon shipment and transfer of title to the customers. In these markets, our illumi gene Our products are generally not subject to a customer right of return except for product recall events under the rules and regulations of the Food and Drug Administration or equivalent agencies outside the United States. In this circumstance, the costs to replace affected products would be accrued at the time a loss was probable and estimable. Trade accounts receivable are recorded in the accompanying consolidated balance sheets at invoiced amounts less provisions for distributor price adjustments under local contracts and doubtful accounts. The allowance for doubtful accounts represents our estimate of probable credit losses and is based on historical write-off experience and known conditions that would likely lead to non-payment. The allowance for doubtful accounts and related metrics, such as days’ sales outstanding, are reviewed monthly. Accounts with past due balances over 90 days are reviewed individually for collectibility. Customer invoices are charged off against the allowance when we believe it is probable that the invoices will not be paid. (j) Research and Development Costs (k) Income Taxes We account for uncertain tax positions using a benefit recognition model with a two-step approach: (i) a more-likely-than-not recognition criterion; and (ii) a measurement attribute that measures the position as the largest amount of tax benefit that is greater than 50% likely of being ultimately realized upon ultimate settlement. If it is not more likely than not that the benefit will be sustained on its technical merits, no benefit is recorded. We recognize accrued interest related to unrecognized tax benefits as a portion of our income tax provision in the consolidated statements of operations. See Note 5. (l) Stock-Based Compensation (m) Comprehensive Income (Loss) (n) Shipping and Handling Costs (o) Non-Income Government-Assessed Taxes (p) Recent Accounting Pronouncements Revenue from Contracts with Customers In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes In February 2016, the FASB issued ASU 2016-02, Leases In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting Issued but not yet effective accounting pronouncements are not expected to have a material impact on the Consolidated Financial Statements. (q) Reclassifications

Magellan Acquisition

Magellan Acquisition	12 Months Ended
	Sep. 30, 2016
Business Combinations [Abstract]
Magellan Acquisition	(2) Magellan Acquisition On March 24, 2016, we acquired all of the outstanding common stock of Magellan Biosciences, Inc., and its wholly-owned subsidiary Magellan Diagnostics, Inc. (collectively, “Magellan”), for $67,874, utilizing the proceeds from a new $60,000 five-year term loan and cash and equivalents on hand. An amount of the acquisition consideration totaling $2,383 remains payable to the sellers, pending the realization of tax benefits for certain net operating loss carryforwards in future tax returns. Headquartered near Boston, Massachusetts, Magellan is a leading manufacturer of FDA-cleared products for the testing of blood to diagnose lead poisoning in children and adults. Magellan is the leading provider of point-of-care lead testing systems in the U.S. As a result of the consideration paid exceeding the preliminary fair value of the net assets acquired, goodwill in the amount of $41,358 was recorded in connection with this acquisition, none of which will be deductible for tax purposes. This goodwill results largely from the addition of Magellan’s complementary customer base and distribution channels, industry reputation in the U.S. as a leader in lead testing, and management talent and workforce. Our fiscal 2016 Consolidated Statement of Operations includes $1,105 of acquisition-related costs related to the Magellan acquisition, which are reflected as Operating Expenses. In addition to Magellan’s results of operations, which are included in our fiscal 2016 Consolidated Statement of Operations and reported as part of the Diagnostics operating segment, the consolidated results for fiscal 2016 also include: (i) $181 of cost of sales related to the roll-out of fair value inventory adjustments for sales of products that were in Magellan’s inventory on the date of acquisition and, therefore, were valued at fair value, rather than manufactured cost, in the opening balance sheet; and (ii) $1,337 of general and administrative expenses related to the depreciation of the fair value adjustment to acquired property, plant and equipment, and the amortization of specific identifiable intangible assets recorded on the opening balance sheet including customer relationships, technology, non-compete agreements, and trade names. The Company’s fiscal 2016 consolidated results include net revenues and net earnings of Magellan totaling $10,034 and $848, respectively, reflecting the items noted above but excluding interest expense on the debt secured by Meridian in connection with the transaction. The recognized preliminary amounts of identifiable assets acquired and liabilities assumed in the acquisition of Magellan are as follows: PRELIMINARY March 24, 2016 Measurement March 24, (as initially Period 2016 reported) Adjustments (as adjusted) Fair value of assets acquired - Cash and equivalents $ 3,400 $ — $ 3,400 Accounts receivable 1,700 — 1,700 Inventories 1,400 — 1,400 Other current assets 300 — 300 Property, plant and equipment 2,800 (200 ) 2,600 Goodwill 42,800 (1,400 ) 41,400 Other intangible assets (estimated useful life): Customer relationships (15 years) 12,600 200 12,800 Technology (10 years) 10,600 — 10,600 Non-compete agreements (2 years) 700 — 700 Trade names (approximate 9 year weighted average) 3,700 (800 ) 2,900 80,000 (2,200 ) 77,800 Fair value of liabilities assumed - Accounts payable and accrued expenses 1,600 100 1,700 Deferred income tax liabilities 10,600 (2,400 ) 8,200 Total consideration paid (including $2,400 accrued to be paid) $ 67,800 $ 100 $ 67,900 As indicated, the allocation of the purchase price and estimated useful lives of property, plant and equipment, and intangible assets shown remain preliminary, pending final completion of valuations. We are currently assessing the amount of tax net operating loss carryforwards available to us. Upon completion of this analysis, an amount will be reclassified from goodwill to deferred taxes. The consolidated pro forma results of the combined entities of Meridian and Magellan, had the acquisition date been October 1, 2014, are as follows for the periods indicated: (UNAUDITED) Fiscal Year Ended September 30, 2016 2015 Net Revenues $ 203,720 $ 211,250 Net Earnings $ 32,675 $ 34,182 These pro forma amounts have been calculated by including the results of Magellan, and adjusting the combined results to give effect to the following, as if the acquisition had been consummated on October 1, 2014, together with the consequential tax effects thereon: (i) remove the effect of transaction costs incurred by the Company ($1,105); (ii) reflect the additional depreciation and amortization that would have been charged in connection with the preliminary fair value adjustments to inventory, property, plant and equipment, and identifiable intangible assets ($800 and $2,885 in fiscal 2016 and fiscal 2015, repectively); (iii) reflect equity-based awards granted under the Company’s 2012 Stock Incentive Plan to certain Magellan employees in accordance with executed employee agreements, and to certain Meridian employees to reward them for their efforts in connection with the transaction ($250 in fiscal 2015); and (iv) reflect the interest expense that would have been incurred on the Company’s $60,000 term note ($690 and $1,685 in fiscal 2016 and fiscal 2015, respectively).

Inventories

Inventories	12 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Inventories	(3) Inventories Inventories are comprised of the following: As of September 30, 2016 2015 Raw materials $ 7,639 $ 7,095 Work-in-process 13,146 10,096 Finished goods - instruments 2,378 1,890 Finished goods - kits and reagents 21,894 16,736 Total $ 45,057 $ 35,817

Bank Credit Arrangements

Bank Credit Arrangements	12 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Bank Credit Arrangements	(4) Bank Credit Arrangements In connection with the acquisition of Magellan (see Note 2), on March 22, 2016 the Company entered into a $60,000 five-year term loan with a commercial bank. The term loan requires quarterly principal and interest payments, with interest at a variable rate tied to LIBOR, and a balloon principal payment at the end of five years. The required principal payments on the term loan for each of the five succeeding fiscal years are as follows: fiscal 2017 - $3,750, fiscal 2018 - $4,500, fiscal 2019 - $5,250, fiscal 2020 - $6,000, and fiscal 2021 - $39,000. Due to the recent execution date of the term loan and interest being determined on a variable rate basis, the fair value of the term loan at September 30, 2016 approximates the current carrying value reflected in the accompanying Consolidated Balance Sheet. In order to limit exposure to volatility in the LIBOR interest rate, the Company and the commercial bank also entered into an interest rate swap that effectively converts the variable interest rate on the term loan to a fixed rate of 2.76%. With an initial notional balance of $60,000, the interest rate swap has been established with critical terms identical to those of the term loan, including (i) notional reduction amounts and dates; (ii) LIBOR settlement rates; (iii) rate reset dates; and (iv) term/maturity. Due to this, the interest swap has been designated as an effective cash flow hedge, with changes in fair value reflected as a separate component of other comprehensive income in the accompanying Consolidated Statements of Comprehensive Income and accumulated other comprehensive loss in the accompanying Consolidated Balance Sheets. At September 30, 2016, the fair value of the interest rate swap was a liability of $729, and is reflected as a non-current liability in the accompanying Consolidated Balance Sheet. This fair value was determined by reference to a third party valuation, and is considered a Level 2 input within the fair value hierarchy of valuation techniques. In addition, the Company continues to maintain a $30,000 revolving credit facility with a commercial bank, which expires March 31, 2021. As there were no borrowings outstanding on this revolving credit facility at September 30, 2016 or September 30, 2015, available borrowings as of both dates totaled $30,000. The term loan and revolving credit facility are collateralized by the business assets of the Company’s U.S. subsidiaries and require compliance with financial covenants that limit the amount of debt obligations and require a minimum level of coverage of fixed charges, as defined in the borrowing agreement. As of September 30, 2016, the Company is in compliance with all covenants. The Company is also required to maintain a cash compensating balance with the bank in the amount of $1,000, pursuant to this bank revolving credit facility and is in compliance with this requirement.

Income Taxes

Income Taxes	12 Months Ended
	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	(5) Income Taxes (a) Earnings before income taxes, and the related provision for income taxes for the years ended September 30, 2016, 2015 and 2014 were as follows: Year Ended September 30, 2016 2015 2014 Domestic $ 44,795 $ 50,653 $ 48,350 Foreign 5,849 4,410 3,758 Total earnings before income taxes $ 50,644 $ 55,063 $ 52,108 Provision (credit) for income taxes - Federal - Current $ 16,178 $ 16,152 $ 15,021 Temporary differences Fixed asset basis differences and depreciation (45 ) 50 108 Intangible asset basis differences and amortization (744 ) (421 ) (210 ) Currently non-deductible expenses and reserves (694 ) 217 50 Stock-based compensation 129 126 59 Tax credit carryforwards 41 250 225 Other, net 181 19 66 Subtotal 15,046 16,393 15,319 State and local 2,421 2,236 1,762 Foreign 948 894 284 Total income tax provision $ 18,415 $ 19,523 $ 17,365 (b) The following is a reconciliation between the statutory U.S. income tax rate and the effective rate derived by dividing the provision for income taxes by earnings before income taxes: Year Ended September 30, 2016 2015 2014 Computed income taxes at statutory rate $ 17,719 35.0 % $ 19,264 35.0 % $ 18,238 35.0 % Increase (decrease) in taxes resulting from - State and local income taxes 1,329 2.6 1,365 2.5 1,061 2.0 Net benefit on foreign dividend — — — — (274 ) (0.5 ) Foreign tax rate differences (337 ) (0.7 ) (217 ) (0.4 ) (430 ) (0.8 ) Qualified domestic production incentives (1,290 ) (2.5 ) (1,197 ) (2.2 ) (1,175 ) (2.3 ) Acquisition-related costs 215 0.4 — — — — Uncertain tax position activity 122 0.2 (25 ) — 164 0.3 Valuation allowance 327 0.7 7 — (288 ) (0.5 ) Other, net 330 0.7 326 0.6 69 0.1 $ 18,415 36.4 % $ 19,523 35.5 % $ 17,365 33.3 % (c) The components of net deferred tax assets were as follows: As of September 30, 2016 2015 Deferred tax assets - Valuation reserves and non-deductible expenses $ 2,366 $ 1,931 Stock compensation expense not deductible 3,110 3,221 Net operating loss and tax credit carryforwards 2,190 590 Basis difference in equity-method investee 302 — Inventory basis differences 1,620 1,186 Other 297 8 Subtotal 9,885 6,936 Less valuation allowance (342 ) (15 ) Deferred tax assets 9,543 6,921 Deferred tax liabilities - Fixed asset basis differences and depreciation (1,526 ) (995 ) Intangible asset basis differences and amortization (10,770 ) (972 ) Deferred tax liabilities (12,296 ) (1,967 ) Net deferred tax (liabilities) assets $ (2,753 ) $ 4,954 For income tax purposes, we have recorded deferred tax assets related to operating loss and tax credit carryforwards in both U.S. and foreign jurisdictions totaling $1,945 and $245, respectively, as of September 30, 2016. At September 30, 2015, such deferred tax assets totaled $590. The operating loss carryforwards in foreign jurisdictions have no expiration date. The operating loss carryforwards in the U.S. expire between 2023 and 2036 at the federal level, and between 2028 and 2036 at the state level. The aggregate amount of federal, state and foreign operating loss carryforwards total $4,956, $3,981 and $836, respectively, at September 30, 2016. The use of the federal and state losses is limited by the change of ownership provisions of the Internal Revenue Code. The realization of deferred tax assets is dependent upon the generation of future taxable income in the applicable jurisdictions. We have considered the levels of currently anticipated pre-tax income in U.S. and foreign jurisdictions in assessing the required level of the deferred tax asset valuation allowance including the characterization of the income as ordinary or capital. Taking into consideration historical and current operating results, and other factors, we believe that it is more likely than not that the net deferred tax asset of $9,543 will be realized. The amount of the net deferred tax asset considered realizable, however, could be reduced in future years if estimates of future taxable income are reduced. Undistributed earnings reinvested indefinitely in our non-U.S. operations were approximately $10,000 at both September 30, 2016 and September 30, 2015. U.S. deferred tax liabilities of approximately $2,000 and $1,800 on such earnings, after consideration of foreign tax credits, have not been recorded as of September 30, 2016 and September 30, 2015, respectively. As described in Note 1, we utilize a comprehensive model for the recognition, measurement, presentation and disclosure of uncertain tax positions, assuming full knowledge of all relevant facts by the applicable tax authorities. The total amount of unrecognized tax benefits at September 30, 2016 and September 30, 2015 related to such positions was $502 and $238, respectively, of which the full amounts would favorably affect the effective tax rate if recognized. We recognize interest and penalties related to uncertain tax positions as a component of our income tax provision. During fiscal 2016, we increased our tax provision by approximately $8 for such penalties and interest, and recorded approximately $85 to the opening balance sheet of Magellan. During fiscal 2015, we decreased our tax provision by approximately $19 for such penalties and interest. We had approximately $130 accrued for the payment of interest and penalties at September 30, 2016 compared to $37 accrued at September 30, 2015. The amount of our liability for uncertain tax positions expected to be paid or settled in the next 12 months is uncertain. A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows: 2016 2015 Unrecognized income tax benefits beginning of year $ 238 $ 316 Additions for tax positions of prior years 264 9 Reductions for tax positions of prior years — (28 ) Tax examination and other settlements — (59 ) Unrecognized income tax benefits at end of year $ 502 $ 238 We are subject to examination by the tax authorities in the U.S. (both federal and state) and the countries of Australia, Belgium, China, England, France, Germany, Holland, Italy and Singapore. In the U.S., open tax years are fiscal 2013, fiscal 2014 and fiscal 2015. In countries outside the U.S., open tax years generally range from fiscal 2011 and forward. However, in Australia, Belgium and Singapore, the utilization of local net operating loss carryforwards extends the statute of limitations for examination well into the foreseeable future.

Employee Benefits

Employee Benefits	12 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Employee Benefits	(6) Employee Benefits (a) Savings and Investment Plan (b) Stock-Based Compensation Plans Each of the 2004 Plan and 2012 Plan authorized the granting of new shares for options, restricted shares or restricted share units for up to 3,000 shares, with the non-granted portion of the 2004 Plan permitted to be carried forward and added to the 2012 Plan authorized limit. As of September 30, 2016, we have granted 1,492 and 1,241 shares under the 2004 Plan and 2012 Plan, respectively, thereby resulting in a remaining authorized limit of 3,267 shares. Options may be granted at exercise prices not less than 100% of the closing market value of the underlying common shares on the date of grant and have maximum terms up to ten years. Vesting schedules for options, restricted shares and restricted share units are established at the time of grant and may be set based on future service periods, achievement of performance targets or a combination thereof. All options contain provisions restricting their transferability and limiting their exercise in the event of termination of employment or the disability or death of the optionee. We recognize compensation expense for all share-based payments made to employees, based upon the fair value of the share-based payment on the date of the grant. During fiscal 2014, we granted approximately 270 restricted share units (with a weighted-average grant date fair value of $24.82 per share) to certain employees, generally with half of each employee’s grant being time-vested restricted share units vesting in total on the fourth anniversary of the grant date, and the remaining half being subject to attainment of a specified earnings target for fiscal 2014. While dividend equivalents were paid on these units throughout fiscal 2014, the target for fiscal 2014 was not met and, with the exception of these awards being held by our Executive Chairman at the time of his death in the fourth quarter of fiscal 2014, the performance-based portion of the restricted share units granted during fiscal 2014 were cancelled. During fiscal 2015, we granted approximately 270 restricted share units (with a weighted-average grant date fair value of $17.91 per share) to certain employees, generally with half of each employee’s grant being time-vested restricted share units vesting in total on the fourth anniversary of the grant date, and the remaining half being subject to attainment of a specified earnings target for fiscal 2015. While dividend equivalents were paid on these units throughout fiscal 2015, the target for fiscal 2015 was not met and the performance-based portion of these restricted share units granted during fiscal 2015 were cancelled. Additionally, during fiscal 2015 in connection with the extension of an Amended and Restated Employment Agreement, we granted to our Chairman and Chief Executive Officer (i) 25 restricted share units (with a grant date fair value of $16.50 per share) to be earned only if specified revenue and earnings per share targets were achieved for fiscal 2015; and (ii) 100 time-vested options (with a weighted-average grant date fair value of $3.73 per share, as included in the options table below), with half vesting September 30, 2015 and half vesting September 30, 2016. As a result of the fiscal 2015 performance targets being achieved, the restricted share units have been earned and the related compensation expense recorded in fiscal 2015. Similar to previous years, during fiscal 2016, we granted approximately 370 restricted share units (with a weighted-average grant date fair value of $19.38 per share) to certain employees, generally with half of each employee’s grant being time-vested restricted share units vesting in total on the fourth anniversary of the grant date, and the remaining half being subject to attainment of a specified earnings target for fiscal 2016. While dividend equivalents were paid on these units throughout fiscal 2016, the target for fiscal 2016 was not met and the performance-based portion of these restricted share units granted during fiscal 2016 have been cancelled. Additionally, during fiscal 2016 in connection with the Amended and Restated Employment Agreement described above, we granted to our Chairman and Chief Executive Officer, 25 restricted share units (with a grant date fair value of $17.03 per share) to be earned only if specified revenue and earnings per share targets were achieved for fiscal 2016. As a result of the fiscal 2016 performance targets not being achieved, the restricted share units have been cancelled. Giving effect to these grants, cancellations and certain other activities for restricted shares and restricted share units throughout the years, including conversions to common shares, forfeitures, and new hire and employee promotion grants, approximately 460 restricted share units remain outstanding as of September 30, 2016, with a weighted-average grant date fair value of $20.17 per share, a weighted-average remaining vesting period of 1.89 years and an aggregate intrinsic value of $8,867. The weighted-average grant date fair value of the approximate 116 restricted share units that vested during fiscal 2016 was $17.38 per share. The amount of stock-based compensation expense reported was $2,911, $3,324 and $3,557 in fiscal 2016, 2015 and 2014, respectively. The fiscal 2016 expense is comprised of $560 related to stock options and $2,351 related to restricted shares and units; the fiscal 2015 expense is comprised of $591 related to stock options and $2,733 related to restricted shares and units; and the fiscal 2014 expense is comprised of $486 related to stock options and $3,071 related to restricted shares and units. The total income tax benefit recognized in the income statement for these stock-based compensation arrangements was $1,100, $1,250 and $1,185, for fiscal 2016, 2015 and 2014, respectively. As of September 30, 2016, we expect future stock compensation expense for unvested options and unvested restricted stock units to total $376 and $2,232, respectively, which will be recognized during fiscal years 2017 through 2020. We recognize compensation expense only for the portion of shares that we expect to vest. As such, we apply estimated forfeiture rates to our compensation expense calculations. These rates have been derived using historical forfeiture data, stratified by several employee groups. During fiscal 2016, 2015 and 2014, we recorded $76, $86 and $108, respectively, in stock compensation expense to adjust estimated forfeiture rates to actual. We have elected to use the Black-Scholes option pricing model to determine grant-date fair value for stock options, with the following assumptions: (i) expected share price volatility based on the average of Meridian’s historical volatility over the options’ expected lives and implied volatility based on the value of tradable call options; (ii) expected life of options based on contractual lives, employees’ historical exercise behavior and employees’ historical post-vesting employment termination behavior; (iii) risk-free interest rates based on treasury rates that correspond to the expected lives of the options; and (iv) dividend yield based on the expected yield on underlying Meridian common stock. Year ended September 30, 2016 2015 2014 Risk-free interest rates 1.63% 2.07% 1.80% Dividend yield 4.4% 3.7% 3.5% Life of option 6.39 yrs. 6.33 yrs. 6.29 yrs. Share price volatility 31% 33% 33% Forfeitures (by employee group) 0%-16% 0%-15% 0%-14% A summary of the status of our stock option plans at September 30, 2016 and changes during the year is presented in the table and narrative below: Options Wtd Avg Wtd Avg Aggregate Outstanding beginning of period 816 $ 20.54 Grants 239 19.02 Exercises (152 ) 15.64 Forfeitures (63 ) 23.64 Cancellations (60 ) 17.88 Outstanding end of period 780 $ 20.97 6.05 $ 604 Exercisable end of period 583 $ 21.42 4.99 $ 560 A summary of the status of our nonvested options as of September 30, 2016, and changes during the year ended September 30, 2016, is presented below: Options Weighted- Nonvested beginning of period 139 $ 4.18 Granted 239 3.46 Vested (121 ) 3.91 Cancelled (60 ) 3.48 Nonvested end of period 197 $ 3.64 The weighted average grant-date fair value of options granted was $3.46, $3.95 and $5.48 for fiscal 2016, 2015 and 2014, respectively. The total intrinsic value of options exercised was $616, $850 and $1,110 for fiscal 2016, 2015 and 2014, respectively. The total grant-date fair value of options that vested during fiscal 2016, 2015 and 2014 was $474, $571 and $701, respectively. Cash received from options exercised was $2,364, $2,478 and $567 for fiscal 2016, 2015 and 2014, respectively. Tax (expense) benefits recorded to additional paid-in capital from option exercises totaled ($70), ($502) and $315 for fiscal 2016, 2015 and 2014, respectively.

Non-Current Liabilities

Non-Current Liabilities	12 Months Ended
	Sep. 30, 2016
Other Liabilities Disclosure [Abstract]
Non-Current Liabilities	(7) Non-Current Liabilities The Company has provided certain post-employment benefits to its Chairman and Chief Executive Officer and its Chief Commercial Officer. These obligations total $1,628 and $1,399 at September 30, 2016 and 2015, respectively. In addition, we are required by the governments of certain of the foreign countries in which we operate to maintain a level of reserves for potential future severance indemnity. These reserves total $565 and $668 at September 30, 2016 and 2015, respectively.

Reportable Segments and Major C

Reportable Segments and Major Concentration Data	12 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Reportable Segments and Major Concentration Data	(8) Reportable Segments and Major Concentration Data Our reportable segments are Diagnostics and Life Science. The Diagnostics segment consists of manufacturing operations for infectious disease products in Cincinnati, Ohio and, as a result of the acquisition of Magellan, manufacturing operations for products detecting elevated lead levels in blood in Billerica, Massachusetts (near Boston), and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany; and Sydney, Australia, and the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents domestically and abroad, including sales and business development offices in Singapore and Beijing, China to further pursue growing revenue opportunities in Asia. Revenues from individual customers constituting 10% or more of consolidated net revenues are as follows: Year Ended September 30, 2016 2015 2014 Customer A $ 20,246 (10 )% $ 29,155 (15 )% $ 28,278 (15 )% Customer B $ 19,585 (10 )% $ 25,276 (13 )% $ 22,780 (12 )% Accounts receivable from these two Diagnostics distributor customers accounted for 16% and 21% of consolidated accounts receivable at September 30, 2016 and September 30, 2015, respectively. The Company’s international revenues totaled $55,291, $52,313 and $57,051 in fiscal years 2016, 2015 and 2014, respectively. Five of our product families – C. difficile, H. pylori illumi pro illumi gene Significant revenue information by country for the Diagnostics and Life Science segments is as follows. Revenues are attributed to the geographic area based on the location to which the product is delivered. Year Ended September 30, 2016 2015 2014 United States $ 120,826 $ 120,599 $ 112,917 Italy 6,599 7,090 8,469 United Kingdom 1,991 1,964 1,942 Japan 1,644 2,603 2,097 France 1,605 1,603 1,841 Belgium 1,501 1,289 1,241 Holland 1,188 1,326 1,613 Canada 1,024 1,315 1,359 Other countries 8,736 8,325 10,021 Total Diagnostics $ 145,114 $ 146,114 $ 141,500 Year Ended September 30, 2016 2015 2014 United States $ 19,965 $ 21,918 $ 18,864 Germany 6,982 5,699 7,232 United Kingdom 6,410 5,782 5,647 China 4,080 2,526 1,003 Australia 3,153 3,590 4,063 France 2,167 2,026 1,633 Japan 1,320 1,158 1,306 Other countries 6,891 6,017 7,584 Total Life Science $ 50,968 $ 48,716 $ 47,332 Identifiable assets for our Italian distribution organization were $8,782 and $8,497 at September 30, 2016 and 2015, respectively. At September 30, 2016, identifiable assets for the Bioline Group’s operations in the U.K., Germany and Australia totaled approximately $14,973, $7,024 and $3,780, respectively; and totaled approximately $15,647, $6,909 and $3,891, respectively, at September 30, 2015. Segment information for the years ended September 30, 2016, 2015 and 2014 is as follows: Diagnostics Life Science Elim (1) Total Fiscal Year 2016 - Net revenues – Third-party $ 145,114 $ 50,968 $ — $ 196,082 Inter-segment 289 893 (1,182 ) — Operating income 38,202 12,997 179 51,378 Depreciation and amortization 5,471 2,247 — 7,718 Capital expenditures 2,690 1,314 — 4,004 Goodwill 42,608 19,374 — 61,982 Other intangible assets 27,534 2,321 — 29,855 Total assets 185,241 66,624 (42 ) 251,823 Fiscal Year 2015 - Net revenues – Third-party $ 146,114 $ 48,716 $ — $ 194,830 Inter-segment 334 1,300 (1,634 ) — Operating income 44,136 12,057 (133 ) 56,060 Depreciation and amortization 4,099 2,510 — 6,609 Capital expenditures 3,112 1,501 — 4,613 Goodwill 1,250 21,099 — 22,349 Other intangible assets 2,364 3,567 — 5,931 Total assets 119,939 63,670 (327 ) 183,282 Fiscal Year 2014 - Net revenues – Third-party $ 141,500 $ 47,332 $ — $ 188,832 Inter-segment 432 1,009 (1,441 ) — Operating income 40,740 11,750 (98 ) 52,392 Depreciation and amortization 4,283 2,981 — 7,264 Capital expenditures 4,176 1,130 — 5,306 Goodwill 1,250 21,943 — 23,193 Other intangible assets 2,756 5,057 — 7,813 Total assets 109,350 67,834 (255 ) 176,929 (1) Eliminations consist of intersegment transactions. A reconciliation of segment operating expenses to consolidated earnings before income taxes for the years ended September 30, 2016, 2015 and 2014 is as follows: Year Ended September 30, 2016 2015 2014 Segment operating income $ 51,378 $ 56,060 $ 52,392 Interest income 67 23 25 Interest expense (897 ) — — Other, net 96 (1,020 ) (309 ) Consolidated earnings before income taxes $ 50,644 $ 55,063 $ 52,108 Transactions between segments are accounted for at established intercompany prices for internal and management purposes with all intercompany amounts eliminated in consolidation.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	(9) Commitments and Contingencies (a) Royalty Commitments - (b) Purchase Commitments - (c) Operating Lease Commitments - (d) Litigation - (e) Indemnifications -

Quarterly Financial Data

Quarterly Financial Data	12 Months Ended
	Sep. 30, 2016
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data	(10) Quarterly Financial Data (Unaudited) The sum of the earnings per common share may not equal the corresponding annual amounts due to interim quarter rounding. For the Quarter Ended in Fiscal 2016 December 31 March 31 June 30 September 30 Net revenues $ 47,160 $ 51,259 $ 50,665 $ 46,998 Gross profit 31,583 33,572 32,909 29,723 Net earnings 8,893 9,091 8,754 5,491 Basic earnings per common share 0.21 0.22 0.21 0.13 Diluted earnings per common share 0.21 0.21 0.21 0.13 Cash dividends per common share 0.20 0.20 0.20 0.20 For the Quarter Ended in Fiscal 2015 December 31 March 31 June 30 September 30 Net revenues $ 48,013 $ 51,545 $ 48,204 $ 47,068 Gross profit 29,237 32,521 30,331 29,793 Net earnings 7,901 10,070 9,102 8,467 Basic earnings per common share 0.19 0.24 0.22 0.20 Diluted earnings per common share 0.19 0.24 0.22 0.20 Cash dividends per common share 0.20 0.20 0.20 0.20

Subsequent Events

Subsequent Events	12 Months Ended
	Sep. 30, 2016
Subsequent Events [Abstract]
Subsequent Events	(11) Subsequent Events We evaluated subsequent events after the balance sheet date of September 30, 2016 and there were no material subsequent events that required recognition or additional disclosure in these financial statements.

Valuation and Qualifying Accoun

Valuation and Qualifying Accounts	12 Months Ended
	Sep. 30, 2016
Valuation and Qualifying Accounts [Abstract]
Valuation and Qualifying Accounts	SCHEDULE II Meridian Bioscience, Inc. and Subsidiaries Valuation and Qualifying Accounts (Dollars in thousands) Years Ended September 30, 2016, 2015 and 2014 Description Balance at Charged to Deductions Other (a) Balance at Year Ended September 30, 2016: Allowance for doubtful accounts $ 248 $ 139 $ (69 ) $ 16 $ 334 Inventory realizability reserves 2,456 1,285 (1,072 ) 11 2,680 Valuation allowances – deferred taxes 15 327 — — 342 Year Ended September 30, 2015: Allowance for doubtful accounts $ 272 $ 73 $ (41 ) $ (56 ) $ 248 Inventory realizability reserves 2,942 208 (590 ) (104 ) 2,456 Valuation allowances – deferred taxes 8 7 — — 15 Year Ended September 30, 2014: Allowance for doubtful accounts $ 233 $ 116 $ (68 ) $ (9 ) $ 272 Inventory realizability reserves 2,499 1,325 (834 ) (48 ) 2,942 Valuation allowances – deferred taxes 296 8 (296 ) — 8 (a) Balances reflect the effects of currency translation and in 2016, the acquisition of Magellan.

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Nature of Business	(a) Nature of Business -
Principles of Consolidation	(b) Principles of Consolidation -
Use of Estimates	(c) Use of Estimates -
Foreign Currency Translation	(d) Foreign Currency Translation
Cash, Cash Equivalents and Investments	(e) Cash, Cash Equivalents and Investments - Our investment portfolio includes the following components: September 30, 2016 September 30, 2015 Cash and Other Cash and Other Overnight repurchase agreements $ 9,988 $ — $ 25,436 $ — Institutional money market funds 10,020 — — — Cash on hand – Restricted — 1,000 — 1,000 Unrestricted 27,218 — 24,537 — Total $ 47,226 $ 1,000 $ 49,973 $ 1,000
Inventories	(f) Inventories illumi gene illumi gene We establish reserves against cost for excess and obsolete materials, finished goods whose shelf life may expire before sale to customers, and other identified exposures. Such reserves were $2,680 and $2,456 at September 30, 2016 and 2015, respectively. We estimate these reserves based on assumptions about future demand and market conditions. If actual demand and market conditions were to be less favorable than such estimates, additional inventory write-downs would be required and recorded in the period known. Such adjustments would negatively affect gross profit margin and overall results of operations.
Property, Plant and Equipment	(g) Property, Plant and Equipment Buildings and improvements - 18 to 40 years Machinery, equipment and furniture - 3 to 10 years Computer equipment and software - 3 to 5 years
Intangible Assets	(h) Intangible Assets - During fiscal 2016, the annual impairment review for our Americas Diagnostics reporting unit consisted of a qualitative assessment. A qualitative assessment is first performed to determine whether it was more likely than not that the fair value of the reporting unit is less than its carrying value using qualitative indicators. In the event that the reporting unit does not pass the qualitative assessment, the reporting unit’s carrying value is compared to its fair value, with fair value of the reporting unit estimated using market and discounted cash flow approaches. Our Americas Diagnostics reporting unit satisfied the qualitative assessment for fiscal 2016. For each of our Bioline and Life Science-U.S. reporting units, we performed a quantitative assessment in order to determine if impairment existed. As part of this assessment, fair value, as determined through a valuation performed by a third party, was calculated via both market (comparable company) and income (discounted cash flows) approaches. Based upon these approaches, as well as an average of the two, the fair values of each reporting unit exceeded their carrying values; therefore, both the Bioline and Life Science-U.S. reporting units satisfied the quantitative assessment for fiscal 2016. The goodwill held by our Magellan reporting unit was recorded at estimated fair value as part of the March 24, 2016 acquisition (see Note 2) and no events have occurred since that date that would indicate the existence of an impairment. Goodwill is considered impaired if the carrying value of the reporting unit exceeds its fair value. We have no intangible assets with indefinite lives other than goodwill. There have been no impairments from the analyses performed for fiscal 2016, 2015 or 2014. During fiscal 2016, goodwill increased $39,633, reflecting $41,358 from the acquisition of Magellan (Diagnostics operating segment; see Note 2) and a $1,725 decrease from the currency translation adjustment on the goodwill of the Life Science segment’s Bioline Group. The decrease of $844 in fiscal 2015 solely reflects the effect of the Bioline Group and the currency translation adjustments thereon. A summary of Meridian’s acquired intangible assets subject to amortization, as of September 30, 2016 and 2015 is as follows: 2016 2015 As of September 30, Gross Accum. Gross Accum. Manufacturing technologies, core products and cell lines $ 21,921 $ 11,540 $ 11,582 $ 10,906 Trade names, licenses and patents 9,037 3,947 6,410 3,296 Customer lists, customer relationships and supply agreeements 24,385 10,511 12,105 9,964 Non-compete agreements 680 170 — — $ 56,023 $ 26,168 $ 30,097 $ 24,166 The actual aggregate amortization expense for these intangible assets for fiscal 2016, 2015 and 2014 was $2,690, $1,748 and $2,039, respectively. The estimated aggregate amortization expense for these intangible assets for each of the five succeeding fiscal years is as follows: fiscal 2017 - $3,671, fiscal 2018 - $3,480, fiscal 2019 - $3,269, fiscal 2020 - $3,107 and fiscal 2021 - $2,510. Long-lived assets, excluding goodwill, are reviewed for impairment when events or circumstances indicate that such assets may not be recoverable at their carrying value. Whether an event or circumstance triggers an impairment is determined by comparing an estimate of the asset’s future undiscounted cash flows to its carrying value. If impairment has occurred, it is measured by a fair-value based calculation. Our ability to recover the carrying value of our intangible assets, both identifiable intangibles and goodwill, is dependent upon the future cash flows of the related acquired businesses and assets. We make judgments and assumptions regarding future cash flows, including sales levels, gross profit margins, operating expense levels, working capital levels, and capital expenditures. With respect to identifiable intangibles and fixed assets, we also make judgments and assumptions regarding useful lives. We consider the following factors in evaluating events and circumstances for possible impairment: (i) significant under-performance relative to historical or projected operating results; (ii) negative industry trends; (iii) sales levels of specific groups of products (related to specific identifiable intangibles); (iv) changes in overall business strategies; and (v) other factors. If actual cash flows are less favorable than projections, this could trigger impairment of intangible assets and other long-lived assets. If impairment were to occur, this would negatively affect overall results of operations. No triggering events have been identified by the Company for fiscal 2016, 2015 or 2014.
Revenue Recognition and Accounts Receivable	(i) Revenue Recognition and Accounts Receivable Revenue for our Diagnostics segment includes revenue for our illumi gene We evaluate whether each deliverable in the arrangement is a separate unit of accounting. The significant deliverables are an instrument, instrument accessories (e.g., printer) and test kits. An instrument and instrument accessories are delivered to the customer prior to the start of the customer utilization period in order to accommodate customer set-up and installation. There is de minimis illumi gene In markets where the test system is not sold via multiple deliverable arrangements, the cost of the instrument and instrument accessories is charged to cost of sales at the time of shipment and transfer of title to the customer. Revenue for the sales of instruments and instrument accessories and test kits is recognized upon shipment and transfer of title to the customers. In these markets, our illumi gene Our products are generally not subject to a customer right of return except for product recall events under the rules and regulations of the Food and Drug Administration or equivalent agencies outside the United States. In this circumstance, the costs to replace affected products would be accrued at the time a loss was probable and estimable. Trade accounts receivable are recorded in the accompanying consolidated balance sheets at invoiced amounts less provisions for distributor price adjustments under local contracts and doubtful accounts. The allowance for doubtful accounts represents our estimate of probable credit losses and is based on historical write-off experience and known conditions that would likely lead to non-payment. The allowance for doubtful accounts and related metrics, such as days’ sales outstanding, are reviewed monthly. Accounts with past due balances over 90 days are reviewed individually for collectibility. Customer invoices are charged off against the allowance when we believe it is probable that the invoices will not be paid.
Research and Development Costs	(j) Research and Development Costs
Income Taxes	(k) Income Taxes
Accounting For Income Tax Uncertainties	We account for uncertain tax positions using a benefit recognition model with a two-step approach: (i) a more-likely-than-not recognition criterion; and (ii) a measurement attribute that measures the position as the largest amount of tax benefit that is greater than 50% likely of being ultimately realized upon ultimate settlement. If it is not more likely than not that the benefit will be sustained on its technical merits, no benefit is recorded. We recognize accrued interest related to unrecognized tax benefits as a portion of our income tax provision in the consolidated statements of operations. See Note 5.
Stock-Based Compensation	(l) Stock-Based Compensation
Comprehensive Income (Loss)	(m) Comprehensive Income (Loss)
Shipping and Handling Costs	(n) Shipping and Handling Costs
Non-Income Government-Assessed Taxes	(o) Non-Income Government-Assessed Taxes
Recent Accounting Pronouncements	(p) Recent Accounting Pronouncements Revenue from Contracts with Customers In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes In February 2016, the FASB issued ASU 2016-02, Leases In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting Issued but not yet effective accounting pronouncements are not expected to have a material impact on the Consolidated Financial Statements.
Reclassifications	(q) Reclassifications

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Components of Cash and Cash Equivalents	Our investment portfolio includes the following components: September 30, 2016 September 30, 2015 Cash and Other Cash and Other Overnight repurchase agreements $ 9,988 $ — $ 25,436 $ — Institutional money market funds 10,020 — — — Cash on hand – Restricted — 1,000 — 1,000 Unrestricted 27,218 — 24,537 — Total $ 47,226 $ 1,000 $ 49,973 $ 1,000
Summary of Acquired Intangible Assets Subject to Amortization	A summary of Meridian’s acquired intangible assets subject to amortization, as of September 30, 2016 and 2015 is as follows: 2016 2015 As of September 30, Gross Accum. Gross Accum. Manufacturing technologies, core products and cell lines $ 21,921 $ 11,540 $ 11,582 $ 10,906 Trade names, licenses and patents 9,037 3,947 6,410 3,296 Customer lists, customer relationships and supply agreeements 24,385 10,511 12,105 9,964 Non-compete agreements 680 170 — — $ 56,023 $ 26,168 $ 30,097 $ 24,166

Magellan Acquisition (Tables)

Magellan Acquisition (Tables)	12 Months Ended
	Sep. 30, 2016
Business Combinations [Abstract]
Schedule of Preliminary Amounts of Identifiable Assets Acquired and Liabilities Assumed in Acquisition	The recognized preliminary amounts of identifiable assets acquired and liabilities assumed in the acquisition of Magellan are as follows: PRELIMINARY March 24, 2016 Measurement March 24, (as initially Period 2016 reported) Adjustments (as adjusted) Fair value of assets acquired - Cash and equivalents $ 3,400 $ — $ 3,400 Accounts receivable 1,700 — 1,700 Inventories 1,400 — 1,400 Other current assets 300 — 300 Property, plant and equipment 2,800 (200 ) 2,600 Goodwill 42,800 (1,400 ) 41,400 Other intangible assets (estimated useful life): Customer relationships (15 years) 12,600 200 12,800 Technology (10 years) 10,600 — 10,600 Non-compete agreements (2 years) 700 — 700 Trade names (approximate 9 year weighted average) 3,700 (800 ) 2,900 80,000 (2,200 ) 77,800 Fair value of liabilities assumed - Accounts payable and accrued expenses 1,600 100 1,700 Deferred income tax liabilities 10,600 (2,400 ) 8,200 Total consideration paid (including $2,400 accrued to be paid) $ 67,800 $ 100 $ 67,900
Business Acquisition, Pro Forma Information	The consolidated pro forma results of the combined entities of Meridian and Magellan, had the acquisition date been October 1, 2014, are as follows for the periods indicated: (UNAUDITED) Fiscal Year Ended September 30, 2016 2015 Net Revenues $ 203,720 $ 211,250 Net Earnings $ 32,675 $ 34,182

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Components of Inventories	Inventories are comprised of the following: As of September 30, 2016 2015 Raw materials $ 7,639 $ 7,095 Work-in-process 13,146 10,096 Finished goods - instruments 2,378 1,890 Finished goods - kits and reagents 21,894 16,736 Total $ 45,057 $ 35,817

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Earnings Before Income Taxes, and Related Provision for Income Taxes	(a) Earnings before income taxes, and the related provision for income taxes for the years ended September 30, 2016, 2015 and 2014 were as follows: Year Ended September 30, 2016 2015 2014 Domestic $ 44,795 $ 50,653 $ 48,350 Foreign 5,849 4,410 3,758 Total earnings before income taxes $ 50,644 $ 55,063 $ 52,108 Provision (credit) for income taxes - Federal - Current $ 16,178 $ 16,152 $ 15,021 Temporary differences Fixed asset basis differences and depreciation (45 ) 50 108 Intangible asset basis differences and amortization (744 ) (421 ) (210 ) Currently non-deductible expenses and reserves (694 ) 217 50 Stock-based compensation 129 126 59 Tax credit carryforwards 41 250 225 Other, net 181 19 66 Subtotal 15,046 16,393 15,319 State and local 2,421 2,236 1,762 Foreign 948 894 284 Total income tax provision $ 18,415 $ 19,523 $ 17,365
Reconciliation Between the Statutory U.S. Income Tax Rate and Effective Rate Derived by Dividing the Provision for Income Taxes by Earnings Before Income Taxes	(b) The following is a reconciliation between the statutory U.S. income tax rate and the effective rate derived by dividing the provision for income taxes by earnings before income taxes: Year Ended September 30, 2016 2015 2014 Computed income taxes at statutory rate $ 17,719 35.0 % $ 19,264 35.0 % $ 18,238 35.0 % Increase (decrease) in taxes resulting from - State and local income taxes 1,329 2.6 1,365 2.5 1,061 2.0 Net benefit on foreign dividend — — — — (274 ) (0.5 ) Foreign tax rate differences (337 ) (0.7 ) (217 ) (0.4 ) (430 ) (0.8 ) Qualified domestic production incentives (1,290 ) (2.5 ) (1,197 ) (2.2 ) (1,175 ) (2.3 ) Acquisition-related costs 215 0.4 — — — — Uncertain tax position activity 122 0.2 (25 ) — 164 0.3 Valuation allowance 327 0.7 7 — (288 ) (0.5 ) Other, net 330 0.7 326 0.6 69 0.1 $ 18,415 36.4 % $ 19,523 35.5 % $ 17,365 33.3 %
Components of Net Deferred Tax Assets	(c) The components of net deferred tax assets were as follows: As of September 30, 2016 2015 Deferred tax assets - Valuation reserves and non-deductible expenses $ 2,366 $ 1,931 Stock compensation expense not deductible 3,110 3,221 Net operating loss and tax credit carryforwards 2,190 590 Basis difference in equity-method investee 302 — Inventory basis differences 1,620 1,186 Other 297 8 Subtotal 9,885 6,936 Less valuation allowance (342 ) (15 ) Deferred tax assets 9,543 6,921 Deferred tax liabilities - Fixed asset basis differences and depreciation (1,526 ) (995 ) Intangible asset basis differences and amortization (10,770 ) (972 ) Deferred tax liabilities (12,296 ) (1,967 ) Net deferred tax (liabilities) assets $ (2,753 ) $ 4,954
Unrecognized Tax Benefits	A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows: 2016 2015 Unrecognized income tax benefits beginning of year $ 238 $ 316 Additions for tax positions of prior years 264 9 Reductions for tax positions of prior years — (28 ) Tax examination and other settlements — (59 ) Unrecognized income tax benefits at end of year $ 502 $ 238

Employee Benefits (Tables)

Employee Benefits (Tables)	12 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Black-Scholes Option Pricing Model to Determine Grant-date Fair Value for Stock Options	We have elected to use the Black-Scholes option pricing model to determine grant-date fair value for stock options, with the following assumptions: (i) expected share price volatility based on the average of Meridian’s historical volatility over the options’ expected lives and implied volatility based on the value of tradable call options; (ii) expected life of options based on contractual lives, employees’ historical exercise behavior and employees’ historical post-vesting employment termination behavior; (iii) risk-free interest rates based on treasury rates that correspond to the expected lives of the options; and (iv) dividend yield based on the expected yield on underlying Meridian common stock. Year ended September 30, 2016 2015 2014 Risk-free interest rates 1.63% 2.07% 1.80% Dividend yield 4.4% 3.7% 3.5% Life of option 6.39 yrs. 6.33 yrs. 6.29 yrs. Share price volatility 31% 33% 33% Forfeitures (by employee group) 0%-16% 0%-15% 0%-14%
Summary of Stock Option Plans	A summary of the status of our stock option plans at September 30, 2016 and changes during the year is presented in the table and narrative below: Options Wtd Avg Wtd Avg Aggregate Outstanding beginning of period 816 $ 20.54 Grants 239 19.02 Exercises (152 ) 15.64 Forfeitures (63 ) 23.64 Cancellations (60 ) 17.88 Outstanding end of period 780 $ 20.97 6.05 $ 604 Exercisable end of period 583 $ 21.42 4.99 $ 560
Summary of Nonvested Options	A summary of the status of our nonvested options as of September 30, 2016, and changes during the year ended September 30, 2016, is presented below: Options Weighted- Nonvested beginning of period 139 $ 4.18 Granted 239 3.46 Vested (121 ) 3.91 Cancelled (60 ) 3.48 Nonvested end of period 197 $ 3.64

Reportable Segments and Major27

Reportable Segments and Major Concentration Data (Tables)	12 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Consolidated Net Revenues	Revenues from individual customers constituting 10% or more of consolidated net revenues are as follows: Year Ended September 30, 2016 2015 2014 Customer A $ 20,246 (10 )% $ 29,155 (15 )% $ 28,278 (15 )% Customer B $ 19,585 (10 )% $ 25,276 (13 )% $ 22,780 (12 )%
Significant Revenue Information by Country for Diagnostics and Life Science Reportable Segments	Significant revenue information by country for the Diagnostics and Life Science segments is as follows. Revenues are attributed to the geographic area based on the location to which the product is delivered. Year Ended September 30, 2016 2015 2014 United States $ 120,826 $ 120,599 $ 112,917 Italy 6,599 7,090 8,469 United Kingdom 1,991 1,964 1,942 Japan 1,644 2,603 2,097 France 1,605 1,603 1,841 Belgium 1,501 1,289 1,241 Holland 1,188 1,326 1,613 Canada 1,024 1,315 1,359 Other countries 8,736 8,325 10,021 Total Diagnostics $ 145,114 $ 146,114 $ 141,500 Year Ended September 30, 2016 2015 2014 United States $ 19,965 $ 21,918 $ 18,864 Germany 6,982 5,699 7,232 United Kingdom 6,410 5,782 5,647 China 4,080 2,526 1,003 Australia 3,153 3,590 4,063 France 2,167 2,026 1,633 Japan 1,320 1,158 1,306 Other countries 6,891 6,017 7,584 Total Life Science $ 50,968 $ 48,716 $ 47,332
Segment Information	Segment information for the years ended September 30, 2016, 2015 and 2014 is as follows: Diagnostics Life Science Elim (1) Total Fiscal Year 2016 - Net revenues – Third-party $ 145,114 $ 50,968 $ — $ 196,082 Inter-segment 289 893 (1,182 ) — Operating income 38,202 12,997 179 51,378 Depreciation and amortization 5,471 2,247 — 7,718 Capital expenditures 2,690 1,314 — 4,004 Goodwill 42,608 19,374 — 61,982 Other intangible assets 27,534 2,321 — 29,855 Total assets 185,241 66,624 (42 ) 251,823 Fiscal Year 2015 - Net revenues – Third-party $ 146,114 $ 48,716 $ — $ 194,830 Inter-segment 334 1,300 (1,634 ) — Operating income 44,136 12,057 (133 ) 56,060 Depreciation and amortization 4,099 2,510 — 6,609 Capital expenditures 3,112 1,501 — 4,613 Goodwill 1,250 21,099 — 22,349 Other intangible assets 2,364 3,567 — 5,931 Total assets 119,939 63,670 (327 ) 183,282 Fiscal Year 2014 - Net revenues – Third-party $ 141,500 $ 47,332 $ — $ 188,832 Inter-segment 432 1,009 (1,441 ) — Operating income 40,740 11,750 (98 ) 52,392 Depreciation and amortization 4,283 2,981 — 7,264 Capital expenditures 4,176 1,130 — 5,306 Goodwill 1,250 21,943 — 23,193 Other intangible assets 2,756 5,057 — 7,813 Total assets 109,350 67,834 (255 ) 176,929 (1) Eliminations consist of intersegment transactions.
Pre-tax Earnings Table	A reconciliation of segment operating expenses to consolidated earnings before income taxes for the years ended September 30, 2016, 2015 and 2014 is as follows: Year Ended September 30, 2016 2015 2014 Segment operating income $ 51,378 $ 56,060 $ 52,392 Interest income 67 23 25 Interest expense (897 ) — — Other, net 96 (1,020 ) (309 ) Consolidated earnings before income taxes $ 50,644 $ 55,063 $ 52,108

Quarterly Financial Data (Table

Quarterly Financial Data (Tables)	12 Months Ended
	Sep. 30, 2016
Quarterly Financial Information Disclosure [Abstract]
Summary of Quarterly Financial Data	For the Quarter Ended in Fiscal 2016 December 31 March 31 June 30 September 30 Net revenues $ 47,160 $ 51,259 $ 50,665 $ 46,998 Gross profit 31,583 33,572 32,909 29,723 Net earnings 8,893 9,091 8,754 5,491 Basic earnings per common share 0.21 0.22 0.21 0.13 Diluted earnings per common share 0.21 0.21 0.21 0.13 Cash dividends per common share 0.20 0.20 0.20 0.20 For the Quarter Ended in Fiscal 2015 December 31 March 31 June 30 September 30 Net revenues $ 48,013 $ 51,545 $ 48,204 $ 47,068 Gross profit 29,237 32,521 30,331 29,793 Net earnings 7,901 10,070 9,102 8,467 Basic earnings per common share 0.19 0.24 0.22 0.20 Diluted earnings per common share 0.19 0.24 0.22 0.20 Cash dividends per common share 0.20 0.20 0.20 0.20

Summary of Significant Accoun29

Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Sep. 30, 2016USD ($)Event	Sep. 30, 2015USD ($)Event	Sep. 30, 2014USD ($)Event	Mar. 24, 2016USD ($)	Sep. 30, 2013USD ($)
Schedule Of Accounting Policies [Line Items]
Deferred income taxes		$ 4,954,000
Currency losses related to a foreign subsidiary intercompany loan being marked-to-market		1,174,000
Intangible Assets Impairments	$ 0	0	$ 0
Indefinite-Lived intangible assets other than goodwill	0
Changes in Goodwill	39,633,000	(844,000)
Goodwill	61,982,000	22,349,000	23,193,000
Amortization of intangible assets	2,690,000	$ 1,748,000	$ 2,039,000
2,017	3,671,000
2,018	3,480,000
2,019	3,269,000
2,020	3,107,000
2,021	$ 2,510,000
Triggering events for impairment analysis | Event	0	0	0
Accrued distributor price adjustments	$ 4,178,000	$ 5,581,000
Expected instrument utilization period	3 years
Period of review of accounts individually	90 days
Likelihood percentage of tax benefit being recognized upon ultimate settlement	50.00%
Currency Translation Adjustment [Member]
Schedule Of Accounting Policies [Line Items]
Changes in Goodwill	$ (1,725,000)
Magellan [Member]
Schedule Of Accounting Policies [Line Items]
Goodwill	$ 41,358,000			$ 41,400,000
Buildings and Improvements [Member] | Minimum [Member]
Schedule Of Accounting Policies [Line Items]
Estimated useful life	18 years
Buildings and Improvements [Member] | Maximum [Member]
Schedule Of Accounting Policies [Line Items]
Estimated useful life	40 years
Machinery, Equipment and Furniture [Member] | Minimum [Member]
Schedule Of Accounting Policies [Line Items]
Estimated useful life	3 years
Machinery, Equipment and Furniture [Member] | Maximum [Member]
Schedule Of Accounting Policies [Line Items]
Estimated useful life	10 years
Computer Equipment and Software [Member] | Minimum [Member]
Schedule Of Accounting Policies [Line Items]
Estimated useful life	3 years
Computer Equipment and Software [Member] | Maximum [Member]
Schedule Of Accounting Policies [Line Items]
Estimated useful life	5 years
Inventory Realizability Reserves [Member]
Schedule Of Accounting Policies [Line Items]
Inventory Valuation Reserves	$ 2,680,000	2,456,000	$ 2,942,000		$ 2,499,000
ASU 2015-17 [Member]
Schedule Of Accounting Policies [Line Items]
Deferred income taxes		$ 3,431,000

Summary of Significant Accoun30

Summary of Significant Accounting Policies - Components of Cash and Cash Equivalents (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 47,226	$ 49,973	$ 43,047	$ 44,282
Overnight Repurchase Agreements [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	9,988	25,436
Institutional Money Market Funds [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	10,020
Cash [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	27,218	24,537
Cash and Equivalents [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	1,000	1,000
Cash and Equivalents [Member] | Other Restricted Cash [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 1,000	$ 1,000

Summary of Significant Accoun31

Summary of Significant Accounting Policies - Summary of Acquired Intangible Assets Subject to Amortization (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Sep. 30, 2015
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 56,023	$ 30,097
Accumulated Amortization	26,168	24,166
Manufacturing Technologies, Core Products and Cell Lines [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	21,921	11,582
Accumulated Amortization	11,540	10,906
Trade Names, Licenses and Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	9,037	6,410
Accumulated Amortization	3,947	3,296
Customer Lists, Customer Relationships, and Supply Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	24,385	12,105
Accumulated Amortization	10,511	$ 9,964
Non-Compete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	680
Accumulated Amortization	$ 170

Magellan Acquisition - Addition

Magellan Acquisition - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 24, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2014	Mar. 22, 2016	Oct. 01, 2014
Business Acquisition [Line Items]
Proceeds from term loan										$ 59,860
Acquisition consideration payable		$ 2,383								2,383
Goodwill		61,982				$ 22,349				61,982	$ 22,349	$ 23,193
Cost of Sales										68,295	72,948	71,589
General and administrative										30,565	27,616	27,389
Net Revenues		46,998	$ 50,665	$ 51,259	$ 47,160	47,068	$ 48,204	$ 51,545	$ 48,013	196,082	194,830	188,832
Net Earnings		5,491	$ 8,754	$ 9,091	$ 8,893	$ 8,467	$ 9,102	$ 10,070	$ 7,901	32,229	35,540	$ 34,743
Interest expense										897
Magellan [Member]
Business Acquisition [Line Items]
Total consideration paid	$ 67,874
Acquisition consideration payable	2,400
Goodwill	41,400	$ 41,358								41,358
Acquisition-related costs										1,105
Cost of Sales										181
General and administrative										1,337
Net Revenues										10,034
Net Earnings										848
Term loan														$ 60,000
Magellan [Member] | Pro Forma [Member]
Business Acquisition [Line Items]
Transaction costs										1,105
Fair value adjustments to inventory, property, plant and equipment and identifiable intangible assets										800	2,885
Equity-based awards granted											250
Interest expense										$ 690	$ 1,685
Magellan [Member] | Five - Year Term Loan [Member]
Business Acquisition [Line Items]
Proceeds from term loan	$ 60,000
Term loan													$ 60,000

Magellan Acquisition - Schedule

Magellan Acquisition - Schedule of Preliminary Amounts of Identifiable Assets Acquired and Liabilities Assumed in Acquisition (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Mar. 24, 2016	Sep. 30, 2015	Sep. 30, 2014
Fair value of assets acquired -
Goodwill	$ 61,982		$ 22,349	$ 23,193
Magellan [Member]
Fair value of assets acquired -
Cash and equivalents		$ 3,400
Accounts receivable		1,700
Inventories		1,400
Other current assets		300
Property, plant and equipment		2,600
Goodwill	$ 41,358	41,400
Other intangible assets:
Fair value of assets acquired net		77,800
Fair value of liabilities assumed -
Accounts payable and accrued expenses		1,700
Deferred income tax liabilities		8,200
Total consideration paid		67,900
Magellan [Member] | As Initially Reported [Member]
Fair value of assets acquired -
Cash and equivalents		3,400
Accounts receivable		1,700
Inventories		1,400
Other current assets		300
Property, plant and equipment		2,800
Goodwill		42,800
Other intangible assets:
Fair value of assets acquired net		80,000
Fair value of liabilities assumed -
Accounts payable and accrued expenses		1,600
Deferred income tax liabilities		10,600
Total consideration paid		67,800
Magellan [Member] | Measurement Period Adjustments [Member]
Fair value of assets acquired -
Property, plant and equipment		(200)
Goodwill		(1,400)
Other intangible assets:
Fair value of assets acquired net		(2,200)
Fair value of liabilities assumed -
Accounts payable and accrued expenses		100
Deferred income tax liabilities		(2,400)
Total consideration paid		100
Magellan [Member] | Customer Relationships [Member]
Other intangible assets:
Other intangible assets		12,800
Magellan [Member] | Customer Relationships [Member] | As Initially Reported [Member]
Other intangible assets:
Other intangible assets		12,600
Magellan [Member] | Customer Relationships [Member] | Measurement Period Adjustments [Member]
Other intangible assets:
Other intangible assets		200
Magellan [Member] | Technology [Member]
Other intangible assets:
Other intangible assets		10,600
Magellan [Member] | Technology [Member] | As Initially Reported [Member]
Other intangible assets:
Other intangible assets		10,600
Magellan [Member] | Non-Compete Agreements [Member]
Other intangible assets:
Other intangible assets		700
Magellan [Member] | Non-Compete Agreements [Member] | As Initially Reported [Member]
Other intangible assets:
Other intangible assets		700
Magellan [Member] | Trade Names [Member]
Other intangible assets:
Other intangible assets		2,900
Magellan [Member] | Trade Names [Member] | As Initially Reported [Member]
Other intangible assets:
Other intangible assets		3,700
Magellan [Member] | Trade Names [Member] | Measurement Period Adjustments [Member]
Other intangible assets:
Other intangible assets		$ (800)

Magellan Acquisition - Schedu34

Magellan Acquisition - Schedule of Preliminary Amounts of Identifiable Assets Acquired and Liabilities Assumed in Acquisition (Parenthetical) (Detail) - USD ($) $ in Thousands	Mar. 24, 2016	Sep. 30, 2016
Business Acquisition [Line Items]
Acquisition consideration payable		$ 2,383
Magellan [Member]
Business Acquisition [Line Items]
Acquisition consideration payable	$ 2,400
Magellan [Member] | As Initially Reported [Member]
Business Acquisition [Line Items]
Acquisition consideration payable	2,400
Magellan [Member] | Measurement Period Adjustments [Member]
Business Acquisition [Line Items]
Acquisition consideration payable	$ 2,400
Magellan [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Estimated useful life	15 years
Magellan [Member] | Customer Relationships [Member] | As Initially Reported [Member]
Business Acquisition [Line Items]
Estimated useful life	15 years
Magellan [Member] | Customer Relationships [Member] | Measurement Period Adjustments [Member]
Business Acquisition [Line Items]
Estimated useful life	15 years
Magellan [Member] | Technology [Member]
Business Acquisition [Line Items]
Estimated useful life	10 years
Magellan [Member] | Technology [Member] | As Initially Reported [Member]
Business Acquisition [Line Items]
Estimated useful life	10 years
Magellan [Member] | Technology [Member] | Measurement Period Adjustments [Member]
Business Acquisition [Line Items]
Estimated useful life	10 years
Magellan [Member] | Non-Compete Agreements [Member]
Business Acquisition [Line Items]
Estimated useful life	2 years
Magellan [Member] | Non-Compete Agreements [Member] | As Initially Reported [Member]
Business Acquisition [Line Items]
Estimated useful life	2 years
Magellan [Member] | Non-Compete Agreements [Member] | Measurement Period Adjustments [Member]
Business Acquisition [Line Items]
Estimated useful life	2 years
Magellan [Member] | Trade Names [Member]
Business Acquisition [Line Items]
Estimated weighted average useful life	9 years
Magellan [Member] | Trade Names [Member] | As Initially Reported [Member]
Business Acquisition [Line Items]
Estimated weighted average useful life	9 years
Magellan [Member] | Trade Names [Member] | Measurement Period Adjustments [Member]
Business Acquisition [Line Items]
Estimated weighted average useful life	9 years

Magellan Acquisition - Business

Magellan Acquisition - Business Acquisition, Pro Forma Information (Detail) - Magellan [Member] - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Business Acquisition [Line Items]
Net Revenues	$ 203,720	$ 211,250
Net Earnings	$ 32,675	$ 34,182

Inventories - Components of Inv

Inventories - Components of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Sep. 30, 2015
Inventory [Line Items]
Raw materials	$ 7,639	$ 7,095
Work-in-process	13,146	10,096
Total	45,057	35,817
Instruments [Member]
Inventory [Line Items]
Finished goods	2,378	1,890
Kits and Reagents [Member]
Inventory [Line Items]
Finished goods	$ 21,894	$ 16,736

Bank Credit Arrangements - Addi

Bank Credit Arrangements - Additional Information (Detail) - USD ($)	12 Months Ended
	Sep. 30, 2016	Mar. 22, 2016	Sep. 30, 2015	Oct. 01, 2014
Debt Instrument [Line Items]
Notional balance	$ 60,000,000
Interest rate swap description	(i) notional reduction amounts and dates; (ii) LIBOR settlement rates; (iii) rate reset dates; and (iv) term/maturity.
Interest rate swap liability	$ 729,000
Bank credit arrangement, fixed interest rate percentage	2.76%
Credit facility with a commercial bank	$ 30,000,000
Expiration date of credit facility	Mar. 31, 2021
Borrowings outstanding under credit facility	$ 0		$ 0
Available borrowings under credit facility	30,000,000		$ 30,000,000
Cash compensating balance	1,000,000
Magellan [Member]
Debt Instrument [Line Items]
Term loan				$ 60,000,000
2,017	3,750,000
2,018	4,500,000
2,019	5,250,000
2,020	6,000,000
2,021	$ 39,000,000
Five - Year Term Loan [Member] | Magellan [Member]
Debt Instrument [Line Items]
Term loan		$ 60,000,000
Balloon principal payment repayment period	5 years

Income Taxes - Earnings Before

Income Taxes - Earnings Before Income Taxes and Related Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2014
Income Tax Disclosure [Abstract]
Domestic	$ 44,795	$ 50,653	$ 48,350
Foreign	5,849	4,410	3,758
Earnings Before Income Taxes	50,644	55,063	52,108
Federal -
Current	16,178	16,152	15,021
Income Tax Provision	18,415	19,523	17,365
Fixed asset basis differences and depreciation	(45)	50	108
Intangible asset basis differences and amortization	(744)	(421)	(210)
Currently non-deductible expenses and reserves	(694)	217	50
Stock-based compensation	129	126	59
Tax credit carryforwards	41	250	225
Other, net	181	19	66
Subtotal	15,046	16,393	15,319
State and local	2,421	2,236	1,762
Foreign	$ 948	$ 894	$ 284

Income Taxes - Reconciliation B

Income Taxes - Reconciliation Between the Statutory U.S. Income Tax Rate and Effective Rate Derived by Dividing the Provision for Income Taxes by Earnings Before Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2014
Income Tax Disclosure [Abstract]
Computed income taxes at statutory rate	$ 17,719	$ 19,264	$ 18,238
Increase (decrease) in taxes resulting from -
State and local income taxes	1,329	1,365	1,061
Net benefit on foreign dividend			(274)
Foreign tax rate differences	(337)	(217)	(430)
Qualified domestic production incentives	(1,290)	(1,197)	(1,175)
Acquisition-related costs	215
Uncertain tax position activity	122	(25)	164
Valuation allowance	327	7	(288)
Other, net	330	326	69
Income Tax Provision	$ 18,415	$ 19,523	$ 17,365
Computed income taxes at statutory rate	35.00%	35.00%	35.00%
State and local income taxes, rate	2.60%	2.50%	2.00%
Net benefit on foreign dividend, rate			(0.50%)
Foreign tax rate differences, rate	(0.70%)	(0.40%)	(0.80%)
Qualified domestic production incentives, rate	(2.50%)	(2.20%)	(2.30%)
Acquisition-related costs, rate	0.40%
Uncertain tax position activity, rate	0.20%		0.30%
Valuation allowance, rate	0.70%		(0.50%)
Other, net, rate	0.70%	0.60%	0.10%
Total, rate	36.40%	35.50%	33.30%

Income Taxes - Components of Ne

Income Taxes - Components of Net Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Sep. 30, 2015
Deferred tax assets -
Valuation reserves and non-deductible expenses	$ 2,366	$ 1,931
Stock compensation expense not deductible	3,110	3,221
Net operating loss and tax credit carryforwards	2,190	590
Basis difference in equity-method investee	302
Inventory basis differences	1,620	1,186
Other	297	8
Subtotal	9,885	6,936
Less valuation allowance	(342)	(15)
Deferred tax assets	9,543	6,921
Deferred tax liabilities -
Fixed asset basis differences and depreciation	(1,526)	(995)
Intangible asset basis differences and amortization	(10,770)	(972)
Deferred tax liabilities	(12,296)	(1,967)
Net deferred tax liabilities	$ (2,753)
Net deferred tax assets		$ 4,954

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Income Taxes Disclosure [Line Items]
Deferred tax assets operating loss and tax credit carryforwards	$ 2,190	$ 590
Deferred tax assets	9,543	6,921
Undistributed earnings	10,000	10,000
Deferred tax liabilities	2,000	1,800
Amount of unrecognized tax benefits which would favorably affect the effective tax rate if recognized	502	238
Increase (decrease) in tax provision for interest and penalties	8	(19)
Accrued for the payment of interest and penalties	$ 130	$ 37
Uncertain tax positions expected to be paid or settled	12 months
Magellan [Member]
Income Taxes Disclosure [Line Items]
Accrued for the payment of interest and penalties	$ 85
Domestic [Member]
Income Taxes Disclosure [Line Items]
Deferred tax assets operating loss and tax credit carryforwards	$ 1,945
Operating loss carryforwards, expiration period start year	2,023
Operating loss carryforwards, expiration period end year	2,036
Aggregate amount of federal, state and foreign operating loss carryforwards	$ 4,956
Open Tax Years	2013, 2014 and 2015
State [Member]
Income Taxes Disclosure [Line Items]
Operating loss carryforwards, expiration period start year	2,028
Operating loss carryforwards, expiration period end year	2,036
Aggregate amount of federal, state and foreign operating loss carryforwards	$ 3,981
Foreign [Member]
Income Taxes Disclosure [Line Items]
Deferred tax assets operating loss and tax credit carryforwards	245
Aggregate amount of federal, state and foreign operating loss carryforwards	$ 836
Open Tax Years	2011 and forward

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Unrecognized income tax benefits beginning of year	$ 238	$ 316
Additions for tax positions of prior years	264	9
Reductions for tax positions of prior years		(28)
Tax examination and other settlements		(59)
Unrecognized income tax benefits at end of year	$ 502	$ 238

Employee Benefits - Additional

Employee Benefits - Additional Information (Detail) $ / shares in Units, $ in Thousands	12 Months Ended
	Sep. 30, 2016USD ($)Stock_Plan$ / sharesshares	Sep. 30, 2015USD ($)$ / sharesshares	Sep. 30, 2014USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of employers contribution as percentage of employees contribution	100.00%
Maximum percentage of employers contribution on eligible compensation	3.00%
Discretionary and matching contributions to plan	$ 1,631	$ 1,567	$ 1,542
Number of active stock-based compensation plan | Stock_Plan	2
Granted, Shares | shares	239,000
Options granted, authorizing limit | shares	3,267,000
Rate of exercise price of underlying common shares	100.00%
Weighted average grant-date fair value | $ / shares	$ 3.46	$ 3.95	$ 5.48
Weighted average remaining vesting period	1 year 10 months 21 days
Number of restricted shares and units vested | shares	116,000
Stock-based compensation	$ 2,911	$ 3,324	$ 3,557
Total income tax benefit recognized in stock-based compensation arrangements	$ 1,100	1,250	1,185
Stock compensation expense expected period for recognition	2017 through 2020
Stock compensation expense to adjust estimated forfeiture rates to actual	$ 76	86	108
Total intrinsic value of options exercised	616	850	1,110
Total grant-date fair value of options that vested	474	571	701
Cash received from options exercised	2,364	2,478	567
Tax benefits recorded to additional paid-in capital from option exercises			$ 315
Tax (expense) recorded to additional paid-in capital from option exercises	$ (70)	$ (502)
Restricted Stock Units and Restricted Stock Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted share units granted | shares	370,000	270,000	270,000
Weighted-average grant date fair value | $ / shares	$ 17.38		$ 24.82
Weighted-average grant date fair value of restricted share units granted | $ / shares	$ 19.38	$ 17.91
Restricted shares and restricted share units outstanding | shares	460,000
Weighted average grant date fair value of outstanding restricted shares and restricted share units | $ / shares	$ 20.17
Intrinsic value of restricted shares and restricted share units	$ 8,867
Stock-based compensation	2,351	$ 2,733	$ 3,071
Stock-based compensation	$ 2,232
Restricted Stock Units and Restricted Stock Shares [Member] | Chief Executive Officer [Member] | Amended And Restated Employment Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted share units granted | shares	25,000	25,000
Weighted-average grant date fair value | $ / shares	$ 17.03	$ 16.50
2004 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for grant | shares	3,000,000
Granted, Shares | shares	1,492,000
Maximum terms	10 years
2012 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for grant | shares	3,000,000
Granted, Shares | shares	1,241,000
Maximum terms	10 years
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 560	$ 591	$ 486
Stock-based compensation	$ 376
Time Vested Stock Options [Member] | Chief Executive Officer [Member] | Amended And Restated Employment Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, Shares | shares		100,000
Weighted average grant-date fair value | $ / shares		$ 3.73

Employee Benefits - Black-Schol

Employee Benefits - Black-Scholes Option Pricing Model to Determine Grant-date Fair Value for Stock Options (Detail)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Risk-free interest rates	1.63%	2.07%	1.80%
Dividend yield	4.40%	3.70%	3.50%
Life of option	6 years 4 months 21 days	6 years 3 months 29 days	6 years 3 months 15 days
Share price volatility	31.00%	33.00%	33.00%
Forfeitures (by employee group) Minimum	0.00%	0.00%	0.00%
Forfeitures (by employee group) Maximum	16.00%	15.00%	14.00%

Employee Benefits - Summary of

Employee Benefits - Summary of Stock Option Plans (Detail) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Sep. 30, 2016USD ($)$ / sharesshares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Outstanding beginning of period, Options | shares	816
Grants, Options | shares	239
Exercises, Options | shares	(152)
Forfeitures, Options | shares	(63)
Cancellations, Options | shares	(60)
Outstanding end of period, Options | shares	780
Exercisable end of period, Options | shares	583
Outstanding beginning of period, Weighted Average Exercise Price | $ / shares	$ 20.54
Grants, Weighted Average Exercise Price | $ / shares	19.02
Exercises, Weighted average exercise price | $ / shares	15.64
Forfeitures, Weighted average exercise price | $ / shares	23.64
Cancellations, Weighted average exercise price | $ / shares	17.88
Outstanding end of period, Weighted Average Exercise Price | $ / shares	20.97
Exercisable end of period, Weighted average exercise price | $ / shares	$ 21.42
Outstanding end of period, Weighted Average remaining life	6 years 18 days
Exercisable end of period, Weighted Average remaining life	4 years 11 months 27 days
Outstanding end of period, Aggregate intrinsic value | $	$ 604
Exercisable end of period, Aggregate intrinsic value | $	$ 560

Employee Benefits - Summary o46

Employee Benefits - Summary of Nonvested Options (Detail) - $ / shares shares in Thousands	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Nonvested beginning of period, Options	139
Granted, Options	239
Vested, Options	(121)
Cancelled, Options	(60)
Nonvested end of period, Options	197	139
Nonvested beginning of period, Weighted Average Grant Date Fair Value	$ 4.18
Granted, Weighted Average Grant Date Fair Value	3.46	$ 3.95	$ 5.48
Vested, Weighted Average Grant Date Fair Value	3.91
Cancelled, Weighted Average Grant Date Fair Value	3.48
Nonvested end of period, Weighted Average Grant Date Fair Value	$ 3.64

Non-Current Liabilities - Addit

Non-Current Liabilities - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Sep. 30, 2015
Liabilities, Noncurrent [Abstract]
Post-retirement benefits obligations	$ 1,628	$ 1,399
Reserves for potential future severance indemnity	$ 565	$ 668

Reportable Segments and Major48

Reportable Segments and Major Concentration Data - Consolidated Net Revenues (Detail) - Customer Concentration Risk [Member] - Revenues [Member] - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2014
Customer A [Member]
Revenue, Major Customer [Line Items]
Revenues	$ 20,246	$ 29,155	$ 28,278
Concentration percentage	10.00%	15.00%	15.00%
Customer B [Member]
Revenue, Major Customer [Line Items]
Revenues	$ 19,585	$ 25,276	$ 22,780
Concentration percentage	10.00%	13.00%	12.00%

Reportable Segments and Major49

Reportable Segments and Major Concentration Data - Additional Information (Detail) $ in Thousands	12 Months Ended
	Sep. 30, 2016USD ($)Customer	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)
Revenues from External Customers and Long-Lived Assets [Line Items]
Identifiable assets	$ 251,823	$ 183,282	$ 176,929
Italy [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Identifiable assets	8,782	8,497
United Kingdom [Member] | Bioline Group [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Identifiable assets	14,973	15,647
Germany [Member] | Bioline Group [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Identifiable assets	7,024	6,909
Australia [Member] | Bioline Group [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Identifiable assets	$ 3,780	$ 3,891
Customer Concentration Risk [Member] | Two Diagnostic Distributor Customers [Member] | Consolidated Accounts Receivable [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of major customers | Customer	2
Concentration risk percentage	16.00%	21.00%
Foreign Customers, Combined International for Diagnostics and Life Science [Member] | Two Diagnostic Distributor Customers [Member] | Revenues [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 55,291	$ 52,313	$ 57,051
Product Concentration Risk [Member] | Revenues [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage	54.00%	59.00%	58.00%
Third-Party Vendor [Member] | Revenues [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage	11.00%	14.00%	14.00%

Reportable Segments and Major50

Reportable Segments and Major Concentration Data - Significant Revenue Information by Country for Diagnostics and Life Science Reportable Segments (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2014
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 46,998	$ 50,665	$ 51,259	$ 47,160	$ 47,068	$ 48,204	$ 51,545	$ 48,013	$ 196,082	$ 194,830	$ 188,832
Diagnostics [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									145,114	146,114	141,500
Diagnostics [Member] | United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									120,826	120,599	112,917
Diagnostics [Member] | Italy [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									6,599	7,090	8,469
Diagnostics [Member] | United Kingdom [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									1,991	1,964	1,942
Diagnostics [Member] | Japan [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									1,644	2,603	2,097
Diagnostics [Member] | France [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									1,605	1,603	1,841
Diagnostics [Member] | Belgium [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									1,501	1,289	1,241
Diagnostics [Member] | Holland [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									1,188	1,326	1,613
Diagnostics [Member] | Canada [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									1,024	1,315	1,359
Diagnostics [Member] | Other Countries [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									8,736	8,325	10,021
Life Science [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									50,968	48,716	47,332
Life Science [Member] | United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									19,965	21,918	18,864
Life Science [Member] | United Kingdom [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									6,410	5,782	5,647
Life Science [Member] | Japan [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									1,320	1,158	1,306
Life Science [Member] | France [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									2,167	2,026	1,633
Life Science [Member] | Germany [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									6,982	5,699	7,232
Life Science [Member] | China [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									4,080	2,526	1,003
Life Science [Member] | Australia [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									3,153	3,590	4,063
Life Science [Member] | Other Countries [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									$ 6,891	$ 6,017	$ 7,584

Reportable Segments and Major51

Reportable Segments and Major Concentration Data - Segment Information (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2014
Segment Reporting Information [Line Items]
Net Revenues	$ 46,998	$ 50,665	$ 51,259	$ 47,160	$ 47,068	$ 48,204	$ 51,545	$ 48,013	$ 196,082	$ 194,830	$ 188,832
Operating income									51,378	56,060	52,392
Depreciation and amortization									7,718	6,609	7,264
Capital expenditures									4,004	4,613	5,306
Goodwill	61,982				22,349				61,982	22,349	23,193
Other intangible assets	29,855				5,931				29,855	5,931	7,813
Total assets	251,823				183,282				251,823	183,282	176,929
Diagnostics [Member]
Segment Reporting Information [Line Items]
Net Revenues									145,114	146,114	141,500
Life Science [Member]
Segment Reporting Information [Line Items]
Net Revenues									50,968	48,716	47,332
Operating Segments [Member] | Diagnostics [Member]
Segment Reporting Information [Line Items]
Net Revenues									145,114	146,114	141,500
Operating income									38,202	44,136	40,740
Depreciation and amortization									5,471	4,099	4,283
Capital expenditures									2,690	3,112	4,176
Goodwill	42,608				1,250				42,608	1,250	1,250
Other intangible assets	27,534				2,364				27,534	2,364	2,756
Total assets	185,241				119,939				185,241	119,939	109,350
Net revenues									289	334	432
Operating Segments [Member] | Life Science [Member]
Segment Reporting Information [Line Items]
Net Revenues									50,968	48,716	47,332
Operating income									12,997	12,057	11,750
Depreciation and amortization									2,247	2,510	2,981
Capital expenditures									1,314	1,501	1,130
Goodwill	19,374				21,099				19,374	21,099	21,943
Other intangible assets	2,321				3,567				2,321	3,567	5,057
Total assets	66,624				63,670				66,624	63,670	67,834
Net revenues									893	1,300	1,009
Eliminations [Member]
Segment Reporting Information [Line Items]
Operating income									179	(133)	(98)
Total assets	$ (42)				$ (327)				(42)	(327)	(255)
Net revenues									$ (1,182)	$ (1,634)	$ (1,441)

Reportable Segments and Major52

Reportable Segments and Major Concentration Data - Pre-tax Earnings Table (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2014
Segment Reporting [Abstract]
Segment operating income	$ 51,378	$ 56,060	$ 52,392
Interest income	67	23	25
Interest expense	(897)
Other, net	96	(1,020)	(309)
Earnings Before Income Taxes	$ 50,644	$ 55,063	$ 52,108

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2014
Commitments Contingencies And Litigation [Line Items]
Annual royalty expenses	$ 3,134,000	$ 3,106,000	$ 3,482,000
2,017	11,970,000
2,018	1,620,000
2,019	63,000
Thereafter	0
Expenses under operating leases	1,966,000	1,797,000	$ 1,951,000
2,017	1,969,000
2,018	1,451,000
2,019	648,000
2,020	198,000
2,021	188,000
Payments for indemnifications	0	0
Liabilities for indemnifications	$ 0	$ 0
Diagnostics [Member]
Commitments Contingencies And Litigation [Line Items]
Percentage of total royalty expense	85.00%
Diagnostics [Member] | Minimum [Member]
Commitments Contingencies And Litigation [Line Items]
Percentage of royalty payable	4.00%
Diagnostics [Member] | Maximum [Member]
Commitments Contingencies And Litigation [Line Items]
Percentage of royalty payable	8.00%

Quarterly Financial Data - Summ

Quarterly Financial Data - Summary of Quarterly Financial Data (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2014
Quarterly Financial Information Disclosure [Abstract]
Net Revenues	$ 46,998	$ 50,665	$ 51,259	$ 47,160	$ 47,068	$ 48,204	$ 51,545	$ 48,013	$ 196,082	$ 194,830	$ 188,832
Gross profit	29,723	32,909	33,572	31,583	29,793	30,331	32,521	29,237	127,787	121,882	117,243
Net Earnings	$ 5,491	$ 8,754	$ 9,091	$ 8,893	$ 8,467	$ 9,102	$ 10,070	$ 7,901	$ 32,229	$ 35,540	$ 34,743
Basic earnings per common share	$ 0.13	$ 0.21	$ 0.22	$ 0.21	$ 0.20	$ 0.22	$ 0.24	$ 0.19	$ 0.77	$ 0.85	$ 0.84
Diluted earnings per common share	0.13	0.21	0.21	0.21	0.20	0.22	0.24	0.19	0.76	0.85	0.83
Cash dividends per common share	$ 0.20	$ 0.20	$ 0.20	$ 0.20	$ 0.20	$ 0.20	$ 0.20	$ 0.20	$ 0.80	$ 0.80	$ 0.79

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2014
Allowance for Doubtful Accounts [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	$ 248	$ 272	$ 233
Charged to Costs and Expenses	139	73	116
Deductions	(69)	(41)	(68)
Other	16	(56)	(9)
Balance at End of Period	334	248	272
Inventory Realizability Reserves [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	2,456	2,942	2,499
Charged to Costs and Expenses	1,285	208	1,325
Deductions	(1,072)	(590)	(834)
Other	11	(104)	(48)
Balance at End of Period	2,680	2,456	2,942
Valuation Allowances - Deferred Taxes [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	15	8	296
Charged to Costs and Expenses	327	7	8
Deductions			(296)
Balance at End of Period	$ 342	$ 15	$ 8